|
Creo Medical Group PLC on Wednesday said it reached a milestone for reimbursement of patients in the US receiving its procedures, highlighting that more patients are set to benefit from safer and more effective treatment options via endoscopic submucosal dissection procedures. The Chepstow, Wales-based medical device company said the American Medical Association Current Procedural Terminology, CPT, editorial panel has issued its summary of panel actions, which confirms the establishment of two new category I CPT reimbursement codes for endoscopic submucosal dissection, or ESD, procedures. Creo Medical said the establishment of these reimbursement codes will enable and encourage the use of ‘next-generation’ products such as its Speedboat, UltraSlim and Speedboat Notch products which are specifically designed for ESD. The company’s products aim to help clinicians with greater precision, safety, and procedural efficiency for complex endoscopic interventions, Creo Medical explained. Creo Medical Chief Executive Officer Craig Gulliford said: ‘This is a transformative moment for patients, clinicians, and the broader gastrointestinal community. The AMA’s decision to establish dedicated CPT codes for ESD will help remove barriers to access, enabling broader adoption of this advanced, minimally invasive procedure in the US. We are proud to have worked alongside leading societies, key opinion leaders, and industry partners to build the clinical evidence base needed to support this milestone. With clearer reimbursement pathways now in place, more patients will benefit from safer, and more effective treatment options utilising Creo’s range of products.’ Creo Medical shares were up 11% to 15.29 pence each on Wednesday afternoon in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
